-
Bryan has 20 years of healthcare experience in developing and commercializing new medical technologies. He is the Founder and CEO of myBiometry, the co-inventor of its technology, and its largest investor. Before founding myBiometry, he held various sales and marketing positions within the Medical Device and Diagnostics Division of Johnson & Johnson, where he focused on Bariatric Surgery and Thoracic Oncology. Before Johnson & Johnson, he was a consultant at a startup working with companies in the health insurance, pharmacy benefit management, and dialysis services segments. Previous clients include UnitedHealth Care, Optum, Wellpoint, DaVita, and BCBS North Carolina. Bryan has a portfolio of 18 patents. He has a bachelor’s degree in business and computer science from Franklin & Marshall College.
LinkedIn
-
Devon has over 22 years of experience developing award-winning medical and in vitro diagnostic (IVD) devices, pharmaceutical companion diagnostics, and life science tools. He has a demonstrable track record of repeatedly delivering commercially successful FDA approved and research use only (RUO) products. The NIH recently recruited Devon to support the Rapid Acceleration for Diagnostics (RADx) TECH program as an advisor/mentor for several companies developing novel COVID-19 related diagnostics. He also serves on the Board of Directors and as an advisor for several biotech startups. Before myBiometry, he served as the Sr. Director of Engineering at Quanterix. He led the stabilization of the existing platform and introduced new platform technology resulting in an IPO in 2017 (market cap $1.6 billion 12/27/2021). Before joining Quanterix, he served as the Director of Engineering for Novartis Companion Diagnostics, where he oversaw engineering, manufacturing, and technology due diligence efforts in support of identifying partners and technologies capable of best-exposing biomarkers of interest to CDx. Before Novartis, he was the Director of Engineering at Ventana, where he served as the Program Leader responsible for ensuring alignment of product capabilities with the overall platform/reagent strategy and leading the entire project team to meet development/launch milestones, budget, and business needs. He oversaw technical teams, key suppliers, executing successful regulatory strategies, driving operations readiness, inventory ramp-up, new product launch, and early commercialization training/support. He was part of the engineering team that successfully sold Ventana to Roche for $3.6 billion. Devon has a portfolio of 7 patents issued or pending. He holds a bachelor’s and master’s degree in mechanical engineering from the University of Arizona.
-
Anmol serves as myBiometry’s COO. He is a Boston area venture advisor, investor, health-tech entrepreneur, and executive. He has played a leading role in many aspects of the startup cycle: from founding companies, leading management teams, helping incubate companies as a consultant, and evaluating opportunities and raising money as an investor and advisor. Anmol has found himself pursuing his passion for healthcare and startups in diverse ways. He previously co-founded Virtify (Healthcare IT focused on regulatory standards for drug/device submissions) and PlayLocal (Govtech Sports providing digital access to drive healthier outcomes). He holds a BS in Business Administration with a minor in Computer Science from Franklin & Marshall College and an MBA from Babson’s Olin School of Management.
-
Tom leads the sensor development at myBiometry as Chief Scientific Officer. He is a Ph.D. chemist with over 12 years of expertise in sensor development, nanomaterials, and coatings. He has played a leading role in various research and development projects: biosensor applications, nanoparticle-mediated drug delivery, ink and coatings development, and advanced composite formulations. He has worked with a broad cross-section of industries including: healthcare, biotechnology, optics, defense, automotive, and consumer electronics. Tom has a passion for biotechnology and has recently returned his focus to healthcare. He has previously worked as the Director of Biosensors and Nanocomposites at NanoLab, a contract R&D firm focused on nanomaterial applications working with startups, Fortune 500 companies and the US Government. Tom has a portfolio of 15 patients. He has a BA in Chemistry from Wheaton College and a Ph.D. in Chemistry from The Pennsylvania State University’s Eberly College of Science.
-
Christie leads quality management at myBiometry. After product development and quality roles at GE, Hologic, and SonaCare Medical, she founded Kasota Engineering to lead startups in establishing Quality Management Systems and navigating the course to bring their products from concept to market. She is part of the NIH's RADx initiative for quick deployment of COVID-19 diagnostics and advises early-stage biotech, medical device, diagnostic, and therapeutic companies from concept through product launch. Her North Star always points us back to Risk Management - building risk management files, coaching teams in risk-based thinking, and integrating risk reduction methodologies strategically throughout the product development cycle. Christie is a mechanical engineer from Purdue, loves mountain biking and geeks out at cool medical technology.
-
Dr. Vreeke has nearly a 30-year history of developing electrochemical Biosensors. He has over 90 issued US patents that disclose various aspects of the reagent systems, design, operation, construction and high-volume manufacture of electrochemical Biosensors. These patents have been exploited in multiple commercial products. The most notable commercial successes were the Dex, FreeStyle and Libre product lines which drew heavily on the fundamental intellection property of which Dr. Vreeke was a co-inventor. These products have generated combined revenues exceeding $20 Billion USD. The impact on patient lives has been significant with over 10 million individuals benefiting from these products.
After leaving TheraSense Dr. Vreeke continued to be productive in the in vitro diagnostics space. He held roles ranging from Research Fellow to VP of R&D. His contributions migrated from the fundamental research into the production and commercialization of the products originating from research efforts.
Board of Directors
-
Mike has over 30 years of executive leadership experience in in vitro diagnostics, biotech and pharma. Mike was the first board member at myBiometry and helped oversee the early phases of technology development. Mike was previously the Global Head of R&D at QIAGEN Molecular Diagnostics where he was responsible for 6 sites and 370 employees covering all QIAGEN platforms and reagent systems. Before QIAGEN, he held executive R&D positions with Novartis Diagnostics and Novartis Pharmaceuticals where he oversaw the companion diagnostics program for oncology and all portfolio and product development responsibilities in blood screening diagnostics. Prior to Novartis, Mike ran the Molecular Diagnostics business for Becton Dickenson where the launched 2 FDA 510(k)-cleared MDx platforms, 6 molecular infectious disease assays and collection devices, 5 additional cleared 510(k)s and grew the business to cumulative $400M revenue within 4 years. Mike has a portfolio of 22 patents issued or pending. He holds a bachelor’s, master’s, and doctorate in Microbiology from the University of Florida.
-
Joe has over 30 years of global medical device, diagnostics and life science experience driving growth in developed and emerging markets, enhancing profitability and cash flow, achieving operational excellence, and developing next generation products, services and technologies. He is an active angel investor and led the last financing at myBiometry. He has been part of four exits as a CEO or investor [Quad Technologies (Bio-Techne), Adeo Health Sciences (Stallergenes-Greer), Firefly Bioworks (Abcam), Stemgent (ReproCell Group of Japan)]. Joe most recently served as the CEO and Director of Cellero Biosciences (an Ampersand Capital company focusing on tools for the immunotherapy segment) and was responsible for the post-acquisition integration of Key Biologics and Astarte Biologics. Cellero was subsequently acquired by Charles River Labs in August of 2020. Prior to Cellero, he was SVP and Consultant for Quanterix helping to prepare the company for its IPO in 2017 (market cap $2.75 billion 02/26/2021). Previously, Joe held EVP and COO roles at Stemgent-Asterand where he negotiated the sale of the Stemgent unit to ReproCell Group, a JASDAQ listed Japanese regenerative medicine company. He then served as the CEO of the combined company. Prior to Stemgent, he was Vice President and General Manager for Becton Dickinson Biosciences, a business unit he grew to 1,000 employees globally and $350MM in revenue. Joe holds a bachelor’s degree in electrical engineering and biology from Northeastern University and master’s degrees in Electrical Engineering and Business Administration from Boston University. He is also a graduate of the Advanced Management Program at Harvard Business School.
-
Joel has been the President of Safety Inc since 1988. Safety Inc is a diversified distributor and manufacturer’s rep of safety equipment and analytical instrumentation. He has a breadth of experience in various sensor technologies, including electrochemical, catalytic, infrared, photoionization, flame ionization, fourier-transform infrared spectroscopy, mass spectrometry, and gas chromatography. Two of Joel’s children have cystic fibrosis, a genetic respiratory illness than includes symptoms of asthma. Joel has a keen interest in combining his professional experience with his personal mission of finding new novel treatments for respiratory illnesses. Joel holds a BS in accounting and a BA in economics from UMass Amherst.
-
Dr. Kisner is a consultant in laboratory medicine and a nationally recognized expert in instrument and reagent selection, workflow design and optimization, and laboratory automation. Dr. Kisner is a valued resource to integrated health systems/academic medical centers and large physician group practices throughout the U.S, assists in-vitro diagnostic companies on product design and commercializing innovation, serves on several scientific advisory boards, and advises private equity firms on investment in the laboratory and diagnostics sectors. Dr. Kisner also served as Chief Science Officer to Davita Clinical Research (DCR) and Chief Laboratory Officer to Davita Laboratories.
In 2003 Dr. Kisner founded and continues to serve as President of NorthEast Clinical & Anatomic Pathology Solutions INC (dba: NECAPS) - laboratory consulting firm specializing in the technical and operational aspects of clinical & anatomic pathology.
Dr. Kisner has assisted several nationally visible clients during his career, including:
• Partners Healthcare - developed a roadmap for their evolution from individual hospital to an IDN network laboratory.
• Cleveland Clinic - designed a transitional pathway integrating quality oversight into their IDN lab.
• LumiraDx - helped their President implement a commercialization strategy for their novel POC platform.
• Akoya BioSciences - guiding them as they transition from a R&D company to a CLIA certified laboratory.
In 2006 Dr. Kisner co-founded ConVerge Diagnostic Services, LLC, an anatomic pathology laboratory with an emphasis on the integration of traditional anatomic pathology services with molecular diagnostics and flow cytometry. After the sale of ConVerge Dx to Water St. Health Partners (WSHP) in 2009, Dr. Kisner served as a consultant to the company until 2011.
Prior to founding NECAPS, Dr. Kisner was COO and Laboratory Director of Path Lab Inc. from 1987-2003. One of the fastest growing and most dynamic integrated health network laboratories in the country, Dr. Kisner was instrumental in helping design, implement and oversee the various management models servicing seven hospitals and six large group practice POLs. His responsibility extended over all the technical and medical aspects of the clinical and anatomic pathology laboratories associated with Path Lab.
Dr. Kisner received his Ph.D. in Clinical Chemistry from the University of Rhode Island, and his MBA from an executive program at Loyola College in Maryland.
LinkedIn
Clinical Advisors
-
Professor of Respiratory Medicine at the University of Oxford and Honorary Consultant Physician at the Oxford University Hospitals.
Professor Pavord has a research interest in the clinical aspects of inflammatory airway diseases and has pioneered the use of non-invasive measures of airway inflammation in the assessment of these conditions. He has identified a number of clinically important phenotypes of inflammatory airway disease, has discovered clinically important biomarkers, and has played a lead role in the clinical development of three of the most promising new treatments for severe airway disease.
He was co-editor of Thorax from 2010-2015, Chief Medical Officer of Asthma UK from 2008-14, Associate Editor of the American Journal of Respiratory and Critical Care Medicine from 2005-10 and has been Associate Editor of the European Respiratory Journal since 2016. He is the author of over 550 publications and has an H-index of 119 making him the 2nd highest cited researcher in asthma worldwide. He received the 2016 European Respiratory Society (ERS) Gold Medal for his research and gave the Cournand Lecture at the 2004 ERS meeting. He chaired the 2017 Lancet Commission on asthma.
-
Specialist in respiratory medicine, clinical researcher, and assistant-professor at the Université de Sherbooke.
He completed a two-year clinical research fellowship in severe asthma and graduated with distinction from his MSc in experimental and translational therapeutics at the University of Oxford. He is undertaking a joint Oxford-Leiden collaboration on risk prediction in asthma. His research themes are biomarker-guided management of airways disease.
-
Professor of Medicine and a pulmonary and critical care specialist with clinical and research expertise in asthma, eosinophilia and related diseases. Professor Wechsler currently serves as Director of Asthma at National Jewish Health (NJH) and Director of the NJH Cohen Family Asthma Institute, where he is charged with developing research, clinical and educational programs in asthma. In 2021, he was named Associate Vice President, Innovation & Industry Relations at National Jewish Health. Prior to coming to NJH in 2012, he was Associate Director of Harvard’s Brigham & Women’s Hospital (BWH) Asthma Research Center, where he designed and led clinical trials in asthma and eosinophilic lung diseases.
His primary research focuses on clinical and translational asthma research, with three main foci of investigation: (i) asthma personalized medicine including genomics, biomarkers and novel therapies; (ii) clinical trials in asthma; and (iii) eosinophilic granulomatosis with polyangiitis (Churg-Strauss Syndrome).
Business Advisors
-
Sharon Cunninghis is an innovator with a demonstrated history of successfully launching consumer and employer tech solutions in the health and benefits space, always with an eye toward improving peoples’ lives. She has 30+ years’ experience in leading the creation of programs that drive better outcomes for members and employers.
Sharon spent most of her career at Mercer, a leading human resource consulting firm, where she was the US Health Leader and responsible for innovation across employer, consumer, and government channels. She held additional leadership roles, including the development of Mercer Marketplace 365, a leader in private exchanges, was the Global Health Benefits consulting leader and worked with many Fortune 500 clients. After Mercer, she most recently helped launched a fintech startup.
She holds a B.S. in Economics from The Wharton School at University of Pennsylvania, where she graduated Cum Laude. She is an Associate of the Society of Actuaries and was named a Top 25 Consultant by Consulting Magazine in 2013.
-
Satish serves as a Technical Advisor to myBiometry. As an entrepreneur and early-stage investor focused on the life sciences and healthcare space, Satish has helped found and/or fund more than a dozen innovative companies in technology, health care, and the life sciences. His primary interests lie in Healthcare IT and at the intersection of drug, medical device and diagnostics development, and software systems development, primarily for accelerating clinical trials and regulatory approvals. He also sits on the Board of Directors for Scripta Insights, ConnectM, Unruly Studios, and Gateway for Cancer Research. Satish mentors and supports entrepreneurs as an executive at TiE ScaleUp and an Executive Fellow in Entrepreneurship at Harvard Business School. He has a BE in Electronics Engineering from Birla Institute of Technology and a Ph.D. in Electrical and Computer Engineering from the University of Iowa.
-
Previously founder and CEO Adeo Health Sciences. Adeo is a disruptive, category-leading (63% market share) company centered around preventing food allergies in infants.
Clarence built the consumer health segment with 40k+ followers, omnichannel distribution of 10k MD offices, 12k grocery doors (Whole Foods, Roche, Target), 6 ecommerce partners (Amazon, Thrive, direct), and over 15 packaging and design awards.
He led clinic development with over 20 partnerships spanning leading pharmaceutical companies (Stallergenes-Greer, Nestle, Nektar), academic institutions (Harvard, MGH, Children’s, Partners), VC institutions (RA Capital, Slow Ventures, Liquid 2, Box Group, Angel groups), and government organizations to fundamentally shift the landscape of increasing food allergies in the U.S.
Clarence authored and managed a global portfolio of patents and trademarks covering over 100 different formulations, compositions of matter, manufacturing processes, and brand identities.
In 2019, Adeo Health Sciences was acquired by Stallergenes-Greer.